Sensus Healthcare

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Sensus Healthcare reports solid Q4 earnings, eyes growth opportunities

Sensus Healthcare's Q4 2022 earnings call highlighted strong revenue performance, strategic growth initiatives, and a focus on expense management. The company aims to leverage opportunities in technology enhancements, market expansion, and revenue growth while addressing challenges related to net income decline and managing expenses effectively.

Sensus Healthcare adapts to inflation challenges, eyes global expansion

Sensus Healthcare navigated a challenging Q1 2023 marked by inflation impacts, focusing on product demand, cost management, and international expansion to drive future growth.
Despite financial setbacks, the company's innovative SRT system, strategic initiatives, and collaborations position it well to capitalize on opportunities in the radiation oncology market and international territories.
Addressing inflation challenges, securing purchase orders efficiently, and leveraging partnerships with hospitals and pharmaceutical companies are key focus areas for Sensus Healthcare's sustainable growth strategy.

Sensus Healthcare reports Q2 growth, eyes profitability amid market challenges

Sensus Healthcare showed improved performance in Q2 but faced challenges with declining profits and negative EBITDA.
The company's strengths lie in new software introductions, marketing expansions, and AI development for product enhancement.
Opportunities include expected profitability, market recovery signs, international expansion, and investor engagement strategies.
To address challenges, Sensus needs to navigate financial pressures, regulatory hurdles, and competitive dynamics effectively.

Sensus Healthcare reports Q3 revenue decline but eyes international expansion

Sensus Healthcare faced revenue decline in Q3 but remains confident in growth prospects, emphasizing proper business management to mitigate risks.
The company's focus on international expansion and innovative clinic management solutions presents opportunities for future revenue growth and market penetration.
Despite challenges in the industry and competitive landscape, Sensus Healthcare's financial stability and strategic initiatives position it for continued success.

Sensus Healthcare excels in Q4, eyes international expansion and innovative revenue models

Sensus Healthcare's Q4 performance reflects strong sales and financial stability, positioning the company for growth.
Innovative products and new revenue models showcase the company's commitment to market expansion and revenue diversification.
While challenges exist in market expansion and cost control, strategic opportunities in international markets and new models offer avenues for growth.

Sensus Healthcare posts stellar Q1 results, eyes global expansion

Sensus Healthcare delivered outstanding results in Q1 2024, marked by robust revenue growth, operational excellence, and financial strength.
While facing challenges in maintaining growth momentum and navigating international markets, the company's strategic strengths and opportunities position it for continued success.
With a focus on innovation, market expansion, and strategic partnerships, Sensus Healthcare is poised to capitalize on its current momentum and drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Sensus Healthcare, Inc. (SRTS) reachead $6.44 at the closing of the latest trading day, reflecting a +1.58% change compared to its last close.

Sensus Healthcare, Inc. (SRTS) Outperforms Broader Market: What You Need to Know

Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Sensus Healthcare (SRTS) is on the Move, Here's Why the Trend Could be Sustainable

The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $5.90, representing a +1.72% change from its previous close.

Sensus Healthcare, Inc. (SRTS) Ascends While Market Falls: Some Facts to Note

Sensus Healthcare (SRTS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Sensus Healthcare (SRTS) Rating Upgrade to Strong Buy

Sensus Healthcare, Inc. (SRTS) closed at $5.80 in the latest trading session, marking a -1.86% move from the prior day.

Sensus Healthcare, Inc. (SRTS) Falls More Steeply Than Broader Market: What Investors Need to Know

Does Sensus Healthcare, Inc. (SRTS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Sensus Healthcare, Inc. (SRTS) is a Great Momentum Stock: Should You Buy?

Here is how Sensus Healthcare, Inc. (SRTS) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

Is Sensus Healthcare (SRTS) Stock Outpacing Its Medical Peers This Year?

Sensus Healthcare (SRTS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Recent Price Trend in Sensus Healthcare (SRTS) is Your Friend, Here's Why

The consensus price target hints at a 65.7% upside potential for Sensus Healthcare (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Sensus Healthcare (SRTS) Could Surge 65.68%: Read This Before Placing a Bet

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Wall Street Analysts Think Sensus Healthcare (SRTS) Is a Good Investment: Is It?

Sensus Healthcare offers equipment for skin problems, with strong demand but vulnerable to economic instability. The company is recovering in 2024, with initiatives for recurring revenue to improve income stability through software and maintenance services. It has begun its expansion to Asia, which in the future could mitigate the risk of customer concentration.

Sensus Healthcare: Recurring Revenue Initiatives Are Exciting

Here is how Sensus Healthcare, Inc. (SRTS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?

From a technical perspective, Sensus Healthcare, Inc. (SRTS) is looking like an interesting pick, as it just reached a key level of support. SRTS recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

Sensus Healthcare, Inc. (SRTS) Recently Broke Out Above the 20-Day Moving Average

Blue Bird

BLBD and SRTS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 13, 2024.

Best Momentum Stocks to Buy for August 13th

The consensus price target hints at a 64.7% upside potential for Sensus Healthcare (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Sensus Healthcare (SRTS) Could Rally 64.74%: Here's is How to Trade

Lakeland Industries

Medical Properties Trust

New York Times

BLBD, SRTS, LAKE, MPW and NYT have been added to the Zacks Rank #1 (Strong Buy) List on August 13, 2024.

New Strong Buy Stocks for August 13th

Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA, IR Joseph Sardano - Chairman and CEO Michael Sardano - President and General Counsel Javier Rampolla - CFO Conference Call Participants Jason Wittes - ROTH Anthony Vendetti - Maxim Group Eduardo Martinez-Montes - H.C. Wainwright & Co. Operator Good day and welcome to the Sensus Healthcare Second Quarter 2024 Financial Results Conference Call.

Sensus Healthcare, Inc. (SRTS) Q2 2024 Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.02 per share a year ago.

Sensus Healthcare, Inc. (SRTS) Q2 Earnings and Revenues Beat Estimates

Revenues of $9.2 million compares with $4.5 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $2.1 million compares with negative $1.0 million a year ago “Fair Deal Agreement” recurring revenue program gaining momentum with 15 agreements signed to date Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla.

Sensus Healthcare Reports Second Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Second Quarter

Investors who want to buy stocks in August might consider searching for stocks gaining more attention from Wall Street. Today we dive into Sensus Healthcare (SRTS) stock and more.

Buying Great Under-the-Radar Stocks During the August Market Pullback

The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $6.25, representing a -1.88% change from its previous close.

Sensus Healthcare, Inc. (SRTS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Sensus Healthcare to Host Second Quarter 2024 Financial Results and Business Update Conference Call on Thursday, August 8, 2024

Sensus Healthcare (SRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sensus Healthcare, Inc. (SRTS) Earnings Expected to Grow: Should You Buy?

BrightSphere Investment Group

ServisFirst Bancshares

The recent surge in analyst coverage for stocks such as BrightSphere (BSIG), Sensus Healthcare (SRTS) and ServisFirst (SFBS) indicates the potential for significant price appreciation in the near term.

3 Stocks in Focus as New Analysts Initiate Coverage

Sensus Healthcare (SRTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for Sensus Healthcare Stock (SRTS)